Newsletter | June 24, 2020

06.24.20 -- COVID-19 & Clinical Trials: Understanding The Long-Term Impact

Featured Editorial
Industry Insights
Fast Track To Flexible Clinical Trials

So, about that clinical trial running right now. In several countries. Clinical setting required. Hmm. We at ISR are speculating that sponsors are shopping around for providers who can adapt, and adapt quickly, to current times. We know that outsourcing is already a challenging undertaking — which CRO is best-suited to conduct a given trial? Who will perform the best? These are loaded questions in normal times, and we provide the reliable data needed to tackle them. 

Modern Oncology Research Landscape: Staying Ahead Of The Game

Companies that can position themselves strategically during preclinical explorations and throughout the development process can bolster their chances of achieving approval and market success. To do so, they must understand key elements of the “new” oncology research landscape.

Actigraphy For Fibromyalgia

Fibromyalgia (FM) is a neuropathic pain that affects millions of people in the United States. It, like most pain conditions, affects daily activity and sleep. The pain sensations are best measured by recording the patient’s own perceptions (patient-reported outcomes), but the related effects of pain on activity and sleep can be measured objectively with actigraphy. Read how actigraphy provides useful insights into the activity patterns in patients with fibromyalgia.

Special Handling: Considering The Clinical Supply Chain In Vaccine Trials

With hundreds of vaccines in research and development worldwide, vaccines are among the fastest growing segments of the biopharmaceutical market today.

Oncology CRO Oversight FSP

To ensure compliance with the updated ICH E6 (R2) guidelines, and to address internal capacity issues, a midsize biopharmaceutical sponsor required qualified support to help ensure appropriate oversight of several large, global CRO providers. By embedding an oversight team within the sponsor’s team, Catalyst was able to alleviate a backlog of activities while providing effective CRO oversight.

Enrollment Goals Exceeded Through High-Touch, High-Tech For A Dermatology Study Of Adolescent Patients

UBC was selected by a large biopharmaceutical company to manage a U.S.-based Phase 4 randomized, placebo-controlled clinical trial of patients with severe acne. As a result of UBC’s innovative services, not only was the enrollment goal achieved, but it was exceeded by 60 percent.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.